Mediar Therapeutics signs licensing deal with Eli Lilly for IPF treatment
Mediar will receive a combined $99m consisting of an upfront payment and near-term milestones.
2022 So far In Venture Capital
EC to terminate Covid-19 vaccine deal with Valneva
J&J enters $99m opioid settlement deal with West Virginia
Supersized Asia and Africa deal to make Merck pill but Covid drug shortage persists
Ligand signs merger agreement with Avista Public Acquisition
Quoin expands distribution deal with ER-Kim for Netherton Syndrome therapy
